This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hull, R. L. Articles by Kahn, S. E. Search for Related Content PubMed PubMed Citation Articles by Hull, R. L. Articles by Kahn, S. E.

Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes

Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington (R.L.H., S.E.K.), Seattle, Washington 98108; Division of Cell Biology, Linköping University (G.T.W.), Linköping, Sweden; and Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University (P.W.), Uppsala, Sweden

Address all correspondence and requests for reprints to: Dr. Steven E. Kahn, Veterans Affairs Puget Sound Health Care System (151), 1660 South Columbian Way, Seattle, Washington 98108. E-mail: skahn{at}u.washington.edu.

Islet amyloid deposition is a pathogenic feature of type 2 diabetes, and these deposits contain the unique amyloidogenic peptide islet amyloid polypeptide. Autopsy studies in humans have demonstrated that islet amyloid is associated with loss of ß-cell mass, but a direct role for amyloid in the pathogenesis of type 2 diabetes cannot be inferred from such studies. Animal studies in both spontaneous and transgenic models of islet amyloid formation have shown that amyloid forms in islets before fasting hyperglycemia and therefore does not arise merely as a result of the diabetic state. Furthermore, the extent of amyloid deposition is associated with both loss of ß-cell mass and impairment in insulin secretion and glucose metabolism, suggesting a causative role for islet amyloid in the islet lesion of type 2 diabetes. These animal studies have also shown that ß-cell dysfunction seems to be an important prerequisite for islet amyloid formation, with increased secretory demand from obesity and/or insulin resistance acting to further increase islet amyloid deposition. Recent in vitro studies suggest that the cytotoxic species responsible for islet amyloid-induced ß-cell death are formed during the very early stages of islet amyloid formation, when islet amyloid polypeptide aggregation commences. Interventions to prevent islet amyloid formation are emerging, with peptide and small molecule inhibitors being developed. These agents could thus lead to a preservation of ß-cell mass and amelioration of the islet lesion in type 2 diabetes.

This work was supported by the Medical Research Service of the Department of Veterans Affairs; Grants DK-02654, DK-17047, and DK-50703; the American Diabetes Association; the Juvenile Diabetes Research Foundation; the Swedish Research Council (Projects 5941, 9237, and 14040); the Swedish Diabetes Association; the Nordic Insulin Fund; the Novo Nordisk Research Foundation; and the Family Ernfors Fund.

Abbreviations: GAG, Glycosaminoglycan; IAPP, islet amyloid polypeptide; SAP, serum amyloid P component.

This article has been cited by other articles:

				V. Dror, T. B. Kalynyak, Y. Bychkivska, M. H. Z. Frey, M. Tee, K. D. Jeffrey, V. Nguyen, D. S. Luciani, and J. D. Johnson Glucose and Endoplasmic Reticulum Calcium Channels Regulate HIF-1{beta} via Presenilin in Pancreatic {beta}-Cells J. Biol. Chem., April 11, 2008; 283(15): 9909 - 9916. [Abstract] [Full Text] [PDF]

				M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, and J. A. Ehses Islet Inflammation in Type 2 Diabetes: From metabolic stress to therapy Diabetes Care, February 1, 2008; 31(Supplement_2): S161 - S164. [Abstract] [Full Text] [PDF]

				S. Nakamura, S. Okabayashi, N. Ageyama, H. Koie, T. Sankai, F. Ono, K. Fujimoto, and K. Terao Transthyretin Amyloidosis and Two Other Aging-Related Amyloidoses in an Aged Vervet Monkey Vet. Pathol., January 1, 2008; 45(1): 67 - 72. [Abstract] [Full Text] [PDF]

				J. J. McManus, A. Lomakin, O. Ogun, A. Pande, M. Basan, J. Pande, and G. B. Benedek From the Cover: Altered phase diagram due to a single point mutation in human {gamma}D-crystallin PNAS, October 23, 2007; 104(43): 16856 - 16861. [Abstract] [Full Text] [PDF]

				S. Casas, R. Gomis, F. M. Gribble, J. Altirriba, S. Knuutila, and A. Novials Impairment of the Ubiquitin-Proteasome Pathway Is a Downstream Endoplasmic Reticulum Stress Response Induced by Extracellular Human Islet Amyloid Polypeptide and Contributes to Pancreatic {beta}-Cell Apoptosis Diabetes, September 1, 2007; 56(9): 2284 - 2294. [Abstract] [Full Text] [PDF]

				A. M. Ruschak and A. D. Miranker Fiber-dependent amyloid formation as catalysis of an existing reaction pathway PNAS, July 24, 2007; 104(30): 12341 - 12346. [Abstract] [Full Text] [PDF]

				S. Zraika, R. L. Hull, J. Udayasankar, A. Clark, K. M. Utzschneider, J. Tong, F. Gerchman, and S. E. Kahn Identification of the Amyloid-Degrading Enzyme Neprilysin in Mouse Islets and Potential Role in Islet Amyloidogenesis Diabetes, February 1, 2007; 56(2): 304 - 310. [Abstract] [Full Text] [PDF]

				J. A. Williamson and A. D. Miranker Direct detection of transient {alpha}-helical states in islet amyloid polypeptide Protein Sci., January 1, 2007; 16(1): 110 - 117. [Abstract] [Full Text] [PDF]

				J. J. Meier, R. Kayed, C.-Y. Lin, T. Gurlo, L. Haataja, S. Jayasinghe, R. Langen, C. G. Glabe, and P. C. Butler Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1317 - E1324. [Abstract] [Full Text] [PDF]

				A. Garcia, S. Xu, F. E. Dewhirst, P. R. Nambiar, and J. G. Fox Enterohepatic Helicobacter species isolated from the ileum, liver and colon of a baboon with pancreatic islet amyloidosis. J. Med. Microbiol., November 1, 2006; 55(Pt 11): 1591 - 1595. [Abstract] [Full Text] [PDF]

				M. D. Lopez-Avalos, V. F. Duvivier-Kali, G. Xu, S. Bonner-Weir, A. Sharma, and G. C. Weir Evidence for a role of the ubiquitin-proteasome pathway in pancreatic islets. Diabetes, May 1, 2006; 55(5): 1223 - 1231. [Abstract] [Full Text] [PDF]

				L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and A. Kapurniotu Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis PNAS, February 14, 2006; 103(7): 2046 - 2051. [Abstract] [Full Text] [PDF]

				M. Y. Donath, J. A. Ehses, K. Maedler, D. M. Schumann, H. Ellingsgaard, E. Eppler, and M. Reinecke Mechanisms of {beta}-Cell Death in Type 2 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S108 - S113. [Abstract] [Full Text] [PDF]

				O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]